These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

525 related articles for article (PubMed ID: 33192053)

  • 1. SGLT2 Inhibitors: A Novel Player in the Treatment and Prevention of Diabetic Cardiomyopathy.
    Li N; Zhou H
    Drug Des Devel Ther; 2020; 14():4775-4788. PubMed ID: 33192053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Empagliflozin and Liraglutide Differentially Modulate Cardiac Metabolism in Diabetic Cardiomyopathy in Rats.
    Trang NN; Chung CC; Lee TW; Cheng WL; Kao YH; Huang SY; Lee TI; Chen YJ
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33503985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Empagliflozin improves left ventricular diastolic function of db/db mice.
    Moellmann J; Klinkhammer BM; Droste P; Kappel B; Haj-Yehia E; Maxeiner S; Artati A; Adamski J; Boor P; Schütt K; Lopaschuk GD; Verma S; Marx N; Lehrke M
    Biochim Biophys Acta Mol Basis Dis; 2020 Aug; 1866(8):165807. PubMed ID: 32353614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Empagliflozin attenuates arrhythmogenesis in diabetic cardiomyopathy by normalizing intracellular Ca
    Kadosaka T; Watanabe M; Natsui H; Koizumi T; Nakao M; Koya T; Hagiwara H; Kamada R; Temma T; Karube F; Fujiyama F; Anzai T
    Am J Physiol Heart Circ Physiol; 2023 Mar; 324(3):H341-H354. PubMed ID: 36607794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sodium-glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy.
    Arow M; Waldman M; Yadin D; Nudelman V; Shainberg A; Abraham NG; Freimark D; Kornowski R; Aravot D; Hochhauser E; Arad M
    Cardiovasc Diabetol; 2020 Jan; 19(1):7. PubMed ID: 31924211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart.
    Li C; Zhang J; Xue M; Li X; Han F; Liu X; Xu L; Lu Y; Cheng Y; Li T; Yu X; Sun B; Chen L
    Cardiovasc Diabetol; 2019 Feb; 18(1):15. PubMed ID: 30710997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus.
    Pancholia AK
    Indian Heart J; 2018; 70(6):915-921. PubMed ID: 30580866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction.
    Liu B; Wang Y; Zhang Y; Yan B
    Curr Top Med Chem; 2019; 19(20):1818-1849. PubMed ID: 31456521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of SGLT2 Inhibitor on Cardiomyopathy in a Rat Model of T2DM: Possible involvement of Cardiac Aquaporins.
    Eltobshy SAG; Messiha R; Metias E; Sarhan M; El-Gamal R; El-Shaieb A; Ghalwash M
    Tissue Cell; 2023 Dec; 85():102200. PubMed ID: 37660414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lessons from the Trials for the Desirable Effects of Sodium Glucose Co-Transporter 2 Inhibitors on Diabetic Cardiovascular Events and Renal Dysfunction.
    Wakisaka M; Kamouchi M; Kitazono T
    Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31726765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SGLT2 inhibition and heart failure-current concepts.
    Custodio JS; Duraes AR; Abreu M; Albuquerque Rocha N; Roever L
    Heart Fail Rev; 2018 May; 23(3):409-418. PubMed ID: 29704192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minireview: are SGLT2 inhibitors heart savers in diabetes?
    Grubić Rotkvić P; Cigrovski Berković M; Bulj N; Rotkvić L
    Heart Fail Rev; 2020 Nov; 25(6):899-905. PubMed ID: 31410757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Empagliflozin prevents cardiomyopathy via sGC-cGMP-PKG pathway in type 2 diabetes mice.
    Xue M; Li T; Wang Y; Chang Y; Cheng Y; Lu Y; Liu X; Xu L; Li X; Yu X; Sun B; Chen L
    Clin Sci (Lond); 2019 Aug; 133(15):1705-1720. PubMed ID: 31337673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial.
    Verma S; Mazer CD; Yan AT; Mason T; Garg V; Teoh H; Zuo F; Quan A; Farkouh ME; Fitchett DH; Goodman SG; Goldenberg RM; Al-Omran M; Gilbert RE; Bhatt DL; Leiter LA; Jüni P; Zinman B; Connelly KA
    Circulation; 2019 Nov; 140(21):1693-1702. PubMed ID: 31434508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diabetes and SGLT2-iss inhibitors in patients with heart failure with preserved or mid-range left ventricular ejection fractions.
    Passantino A; Rizzo C; Scrutinio D; Palazzuoli A
    Heart Fail Rev; 2023 May; 28(3):683-695. PubMed ID: 34725782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus.
    Berg DD; Wiviott SD; Scirica BM; Gurmu Y; Mosenzon O; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Johanson P; Johansson PA; Langkilde AM; Raz I; Braunwald E; Sabatine MS
    Circulation; 2019 Nov; 140(19):1569-1577. PubMed ID: 31474116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. mTORC1 and SGLT2 Inhibitors-A Therapeutic Perspective for Diabetic Cardiomyopathy.
    Saha S; Fang X; Green CD; Das A
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure.
    Reed JW
    Vasc Health Risk Manag; 2016; 12():393-405. PubMed ID: 27822054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
    Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
    Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal and Cardiac Implications of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors: The State of the Science.
    Cruz JE; Ahuja T; Bridgeman MB
    Ann Pharmacother; 2018 Dec; 52(12):1238-1249. PubMed ID: 29911393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.